Pathomechanistic Networks of Motor System Injury in Amyotrophic Lateral Sclerosis
Curr Neuropharmacol. 2023 Aug 24. doi: 10.2174/1570159X21666230824091601. Online ahead of print.ABSTRACTAmyotrophic Lateral Sclerosis (ALS) is the most common, adult-onset, progressive motor neurodegenerative disorder that results in death within 3 years of the clinical diagnosis. Due to the clinicopathological heterogeneity, any reliable biomarkers for diagnosis or prognosis of ALS have not been identified till date. Moreover, the only three clinically approved treatments are not uniformly effective in slowing the disease progression. Over the last 15 years, there has been a rapid advancement in research on the complex pa...
Source: Current Neuropharmacology - August 25, 2023 Category: Drugs & Pharmacology Authors: Bedaballi Dey Arvind Kumar Anant Bahadur Patel Source Type: research
Pathomechanistic Networks of Motor System Injury in Amyotrophic Lateral Sclerosis
Curr Neuropharmacol. 2023 Aug 24. doi: 10.2174/1570159X21666230824091601. Online ahead of print.ABSTRACTAmyotrophic Lateral Sclerosis (ALS) is the most common, adult-onset, progressive motor neurodegenerative disorder that results in death within 3 years of the clinical diagnosis. Due to the clinicopathological heterogeneity, any reliable biomarkers for diagnosis or prognosis of ALS have not been identified till date. Moreover, the only three clinically approved treatments are not uniformly effective in slowing the disease progression. Over the last 15 years, there has been a rapid advancement in research on the complex pa...
Source: Current Neuropharmacology - August 25, 2023 Category: Drugs & Pharmacology Authors: Bedaballi Dey Arvind Kumar Anant Bahadur Patel Source Type: research
Pathomechanistic Networks of Motor System Injury in Amyotrophic Lateral Sclerosis
Curr Neuropharmacol. 2023 Aug 24. doi: 10.2174/1570159X21666230824091601. Online ahead of print.ABSTRACTAmyotrophic Lateral Sclerosis (ALS) is the most common, adult-onset, progressive motor neurodegenerative disorder that results in death within 3 years of the clinical diagnosis. Due to the clinicopathological heterogeneity, any reliable biomarkers for diagnosis or prognosis of ALS have not been identified till date. Moreover, the only three clinically approved treatments are not uniformly effective in slowing the disease progression. Over the last 15 years, there has been a rapid advancement in research on the complex pa...
Source: Current Neuropharmacology - August 25, 2023 Category: Drugs & Pharmacology Authors: Bedaballi Dey Arvind Kumar Anant Bahadur Patel Source Type: research
Pathomechanistic Networks of Motor System Injury in Amyotrophic Lateral Sclerosis
Curr Neuropharmacol. 2023 Aug 24. doi: 10.2174/1570159X21666230824091601. Online ahead of print.ABSTRACTAmyotrophic Lateral Sclerosis (ALS) is the most common, adult-onset, progressive motor neurodegenerative disorder that results in death within 3 years of the clinical diagnosis. Due to the clinicopathological heterogeneity, any reliable biomarkers for diagnosis or prognosis of ALS have not been identified till date. Moreover, the only three clinically approved treatments are not uniformly effective in slowing the disease progression. Over the last 15 years, there has been a rapid advancement in research on the complex pa...
Source: Current Neuropharmacology - August 25, 2023 Category: Drugs & Pharmacology Authors: Bedaballi Dey Arvind Kumar Anant Bahadur Patel Source Type: research
Pathomechanistic Networks of Motor System Injury in Amyotrophic Lateral Sclerosis
Curr Neuropharmacol. 2023 Aug 24. doi: 10.2174/1570159X21666230824091601. Online ahead of print.ABSTRACTAmyotrophic Lateral Sclerosis (ALS) is the most common, adult-onset, progressive motor neurodegenerative disorder that results in death within 3 years of the clinical diagnosis. Due to the clinicopathological heterogeneity, any reliable biomarkers for diagnosis or prognosis of ALS have not been identified till date. Moreover, the only three clinically approved treatments are not uniformly effective in slowing the disease progression. Over the last 15 years, there has been a rapid advancement in research on the complex pa...
Source: Current Neuropharmacology - August 25, 2023 Category: Drugs & Pharmacology Authors: Bedaballi Dey Arvind Kumar Anant Bahadur Patel Source Type: research
Targeting Histone 3 Variants Epigenetic Landscape and Inhibitory Immune Checkpoints: An Option for Paediatric Brain Tumours Therapy
Curr Neuropharmacol. 2023 Aug 15. doi: 10.2174/1570159X21666230809110444. Online ahead of print.ABSTRACTDespite little progress in survival rates with regular therapies, which do not provide complete care for curing pediatric brain tumors (PBTs), there is an urgent need for novel strategies to overcome the toxic effects of conventional therapies to treat PBTs. The co-inhibitory immune checkpoint molecules, e.g., CTLA-4, PD-1/PD-L1, etc., and epigenetic alterations in histone variants, e.g., H3K27me3 that help in immune evasion at tumor microenvironment have not gained much attention in PBTs treatment. However, key epigenet...
Source: Current Neuropharmacology - August 22, 2023 Category: Drugs & Pharmacology Authors: Sarasa Meenakshi Krushna Ch Maharana Lokesh Nama V Udaya Kumar Sameer Dhingra Velayutham Ravichandiran Krishna Murti Nitesh Kumar Source Type: research
Targeting Histone 3 Variants Epigenetic Landscape and Inhibitory Immune Checkpoints: An Option for Paediatric Brain Tumours Therapy
Curr Neuropharmacol. 2023 Aug 15. doi: 10.2174/1570159X21666230809110444. Online ahead of print.ABSTRACTDespite little progress in survival rates with regular therapies, which do not provide complete care for curing pediatric brain tumors (PBTs), there is an urgent need for novel strategies to overcome the toxic effects of conventional therapies to treat PBTs. The co-inhibitory immune checkpoint molecules, e.g., CTLA-4, PD-1/PD-L1, etc., and epigenetic alterations in histone variants, e.g., H3K27me3 that help in immune evasion at tumor microenvironment have not gained much attention in PBTs treatment. However, key epigenet...
Source: Current Neuropharmacology - August 22, 2023 Category: Drugs & Pharmacology Authors: Sarasa Meenakshi Krushna Ch Maharana Lokesh Nama V Udaya Kumar Sameer Dhingra Velayutham Ravichandiran Krishna Murti Nitesh Kumar Source Type: research
Targeting Histone 3 Variants Epigenetic Landscape and Inhibitory Immune Checkpoints: An Option for Paediatric Brain Tumours Therapy
Curr Neuropharmacol. 2023 Aug 15. doi: 10.2174/1570159X21666230809110444. Online ahead of print.ABSTRACTDespite little progress in survival rates with regular therapies, which do not provide complete care for curing pediatric brain tumors (PBTs), there is an urgent need for novel strategies to overcome the toxic effects of conventional therapies to treat PBTs. The co-inhibitory immune checkpoint molecules, e.g., CTLA-4, PD-1/PD-L1, etc., and epigenetic alterations in histone variants, e.g., H3K27me3 that help in immune evasion at tumor microenvironment have not gained much attention in PBTs treatment. However, key epigenet...
Source: Current Neuropharmacology - August 22, 2023 Category: Drugs & Pharmacology Authors: Sarasa Meenakshi Krushna Ch Maharana Lokesh Nama V Udaya Kumar Sameer Dhingra Velayutham Ravichandiran Krishna Murti Nitesh Kumar Source Type: research
Antioxidants, Hormetic Nutrition, and Autism
Curr Neuropharmacol. 2023 Aug 17. doi: 10.2174/1570159X21666230817085811. Online ahead of print.ABSTRACTAutism spectrum disorder (ASD) includes a heterogeneous group of complex neurodevel opmental disorders characterized by atypical behaviors with two core pathological manifestations: deficits in social interaction/communication and repetitive behaviors, which are associated with disturbed redox homeostasis. Modulation of cellular resilience mechanisms induced by low levels of stressors represents a novel approach for the development of therapeutic strategies, and in this context, neuroprotective effects of a wide range of...
Source: Current Neuropharmacology - August 18, 2023 Category: Drugs & Pharmacology Authors: Modafferi Sergio Lupo Gabriella Tomasello Mario Rampulla Francesco Ontario Marialaura Scuto Maria Trovato Salinaro Angela Arcidiacono Antonio Anfuso Carmelina Daniela Legmouz Maria Azzaoui Fatima-Zahra Palmeri Agostino Spano' Sestina Biamonte Francesca Ca Source Type: research
Stress, Environment and Early Psychosis
Curr Neuropharmacol. 2023 Aug 17. doi: 10.2174/1570159X21666230817153631. Online ahead of print.ABSTRACTExisting literature provides extended evidence of the close relationship between stress dysregulation, environmental insults, and psychosis onset. Early stress can sensitize genetically vulnerable individuals to future stress, modifying their risk for developing psychotic phenomena. Neuro-biological substrate of the aberrant stress response to hypothalamic-pituitary-adrenal axis dysregula-tion, disrupted inflammation processes, oxidative stress increase, gut dysbiosis, and altered brain sig-naling, provides mechanistic l...
Source: Current Neuropharmacology - August 18, 2023 Category: Drugs & Pharmacology Authors: Lida-Alkisti Xenaki Stefanos Dimitrakopoulos Mirjana Selakovic Nikos Stefanis Source Type: research
Separation of Channels Subserving Approach and Avoidance/Escape at the Level of the Basal Ganglia and Related Brainstem Structures
Curr Neuropharmacol. 2023 Aug 18. doi: 10.2174/1570159X21666230818154903. Online ahead of print.ABSTRACTThe basal ganglia have the key function of directing our behavior in the context of events from our environment and/or our internal state. This function relies on afferents targeting the main input structures of the basal ganglia, entering bids for action selection at the level of the striatum or sig- nals for behavioral interruption at the level of the subthalamic nucleus, with behavioral reselection facilitated by dopamine signaling. Numerous experiments have studied action selection in relation to inputs from the cere...
Source: Current Neuropharmacology - August 18, 2023 Category: Drugs & Pharmacology Authors: V éronique Coizet Racha Al Tannir Arnaud Pautrat Paul G Overton Source Type: research
Antioxidants, Hormetic Nutrition, and Autism
Curr Neuropharmacol. 2023 Aug 17. doi: 10.2174/1570159X21666230817085811. Online ahead of print.ABSTRACTAutism spectrum disorder (ASD) includes a heterogeneous group of complex neurodevel opmental disorders characterized by atypical behaviors with two core pathological manifestations: deficits in social interaction/communication and repetitive behaviors, which are associated with disturbed redox homeostasis. Modulation of cellular resilience mechanisms induced by low levels of stressors represents a novel approach for the development of therapeutic strategies, and in this context, neuroprotective effects of a wide range of...
Source: Current Neuropharmacology - August 18, 2023 Category: Drugs & Pharmacology Authors: Modafferi Sergio Lupo Gabriella Tomasello Mario Rampulla Francesco Ontario Marialaura Scuto Maria Trovato Salinaro Angela Arcidiacono Antonio Anfuso Carmelina Daniela Legmouz Maria Azzaoui Fatima-Zahra Palmeri Agostino Spano' Sestina Biamonte Francesca Ca Source Type: research
Stress, Environment and Early Psychosis
Curr Neuropharmacol. 2023 Aug 17. doi: 10.2174/1570159X21666230817153631. Online ahead of print.ABSTRACTExisting literature provides extended evidence of the close relationship between stress dysregulation, environmental insults, and psychosis onset. Early stress can sensitize genetically vulnerable individuals to future stress, modifying their risk for developing psychotic phenomena. Neuro-biological substrate of the aberrant stress response to hypothalamic-pituitary-adrenal axis dysregula-tion, disrupted inflammation processes, oxidative stress increase, gut dysbiosis, and altered brain sig-naling, provides mechanistic l...
Source: Current Neuropharmacology - August 18, 2023 Category: Drugs & Pharmacology Authors: Lida-Alkisti Xenaki Stefanos Dimitrakopoulos Mirjana Selakovic Nikos Stefanis Source Type: research
Separation of Channels Subserving Approach and Avoidance/Escape at the Level of the Basal Ganglia and Related Brainstem Structures
Curr Neuropharmacol. 2023 Aug 18. doi: 10.2174/1570159X21666230818154903. Online ahead of print.ABSTRACTThe basal ganglia have the key function of directing our behavior in the context of events from our environment and/or our internal state. This function relies on afferents targeting the main input structures of the basal ganglia, entering bids for action selection at the level of the striatum or sig- nals for behavioral interruption at the level of the subthalamic nucleus, with behavioral reselection facilitated by dopamine signaling. Numerous experiments have studied action selection in relation to inputs from the cere...
Source: Current Neuropharmacology - August 18, 2023 Category: Drugs & Pharmacology Authors: V éronique Coizet Racha Al Tannir Arnaud Pautrat Paul G Overton Source Type: research
Antioxidants, Hormetic Nutrition, and Autism
Curr Neuropharmacol. 2023 Aug 17. doi: 10.2174/1570159X21666230817085811. Online ahead of print.ABSTRACTAutism spectrum disorder (ASD) includes a heterogeneous group of complex neurodevel opmental disorders characterized by atypical behaviors with two core pathological manifestations: deficits in social interaction/communication and repetitive behaviors, which are associated with disturbed redox homeostasis. Modulation of cellular resilience mechanisms induced by low levels of stressors represents a novel approach for the development of therapeutic strategies, and in this context, neuroprotective effects of a wide range of...
Source: Current Neuropharmacology - August 18, 2023 Category: Drugs & Pharmacology Authors: Modafferi Sergio Lupo Gabriella Tomasello Mario Rampulla Francesco Ontario Marialaura Scuto Maria Trovato Salinaro Angela Arcidiacono Antonio Anfuso Carmelina Daniela Legmouz Maria Azzaoui Fatima-Zahra Palmeri Agostino Spano' Sestina Biamonte Francesca Ca Source Type: research
